Request Demo
Last update 28 Feb 2026
Insulin Aspart Biosimilar (Xentria)
Last update 28 Feb 2026
Overview
Basic Info
Drug Type Biosimilar, Peptide Hormone |
Synonyms Insulin aspart Biosimilar (Xentria, Inc.), NKF-INS(A), 门冬胰岛素生物类似药（Xentria, Inc.） |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 31953
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Insulin Aspart Biosimilar (Xentria)NCT07165652
A Single Center, Single-dose, Double-blind, Randomized, Three-period, Three-treatment, Six-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® Using the Euglycemic Clamp Technique in Healthy Male Adult Volunteers
NCT06492226
A Single-center, Single-dose, Double-blind, Randomized, Three-period, Three-treatment, Six-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® Using the Euglycemic Clamp Technique in Healthy Male Adult Volunteers
100 Clinical Results associated with Insulin Aspart Biosimilar (Xentria)
Login to view more data
100 Translational Medicine associated with Insulin Aspart Biosimilar (Xentria)
Login to view more data
100 Patents (Medical) associated with Insulin Aspart Biosimilar (Xentria)
Login to view more data
100 Deals associated with Insulin Aspart Biosimilar (Xentria)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endocrine System Diseases | Phase 1 | South Africa | 30 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 54 | (EU-NovoRapid®) | kxerlifsme(brquetfkbk) = nxmjmiotbm gztyukbqeg (byyhrbnimw, 18.426) View more | - | 21 Jan 2026 | |
(US-NovoLog®) | kxerlifsme(brquetfkbk) = xeabsipyvr gztyukbqeg (byyhrbnimw, 18.711) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free